Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ERN1 | O75460 | 14/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5735288 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL273404 | 0.85 | ERN1 (0.56) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL29432755 | 0.85 | ERN1 (0.56) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL4600135 | 0.84 | ALDH1A1 (0.62) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL19792588 | 0.83 | ERN1 (0.71) | ALDH1A1MAPTERN1KDM4EMEN1 | |
| SCHEMBL4599426 | 0.83 | ERN1 (0.54) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL18003639 | 0.82 | ALDH1A1 (0.67) | ALDH1A1MAPTERN1KDM4ETDP1 | |
| SCHEMBL8322837 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTERN1KDM4EMEN1 | |
| SCHEMBL21780501 | 0.82 | ERN1 (0.50) | ALDH1A1MAPTERN1KDM4ETSHR | |
| SCHEMBL4735020 | 0.82 | ERN1 (0.49) | ALDH1A1MAPTERN1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067535-B2 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKI CO., LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1323713-A1 | 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES FOR THEIR SYNTHESIS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | CYP1B1, MAOB, HTR1B | ALDH1A1 136/4885MAPT 3253/4885ERN1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.